TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05807854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: The surgeon reattaches the torn tendon to the bone with anchors and sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty
Description: It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
Study: NCT05422703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft cold diet
Description: For the day of surgery
Study: NCT06168461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 162mg aspirin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT06788522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant pills (10-20 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pills
Study: NCT06787222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin 0.025% + Z. officinale patch
Description: Material used for patch formulation were 3,15 grams of polyvinyl alcohol, 4,2 grams of polyvinyl pyrrolidone, 12,6 ml distilled water, and 1,05 grams of Z. officinale extract.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin 0.025% cream
Description: no Z. officinale patch applied after tretinoin 0.025% application
Study: NCT06787235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet
Description: The modified Atkins KD is defined as \<20g carbohydrate per day with freely allowed protein consumption. Recommended protein and fat intake will be calculated for each participant based on their energy needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual nutritional consultation
Description: The nutritional consultation will be provided by a dietician to improve individual health
Study: NCT06787716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The whole body vibration
Description: Patients in the study group will receive the traditional physical therapy program first (passive and active ROM exercises, stretching and strengthening exercises) for 60 minutes, 3 days/ week for 12 weeks.This will be followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program will be three sessions a week for 12 weeks. WBV duration started with 10 min at the 1st week up to 35 min at the 12th week, with a regular increase of five minutes every two successive weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: The traditional physical therapy program
Description: The traditional physical therapy program will be three days a week for 12 weeks. The program will include 60 minutes of a supervised and individualized exercise program including passive and active exercises of the hip, knee, and ankle joints, stretching exercises for the Calf and hamstring muscles followed by strengthening exercises of the hip, knee, ankle, and foot muscles. To improve the strength, free weights will be used for all exercises. During the first week, 50 to 60% of the repetitions maximum test will be set as the starting weight. Then, from the second week to the sixth, the weight will be increased to 70%-75% of three repetitions maximum (3 sets, 4-10 repetitions). The training amplitude then will be raised to 80%-85% of the three-repetition maximum (3 sets, 8-12 repetitions) that will be continued through weeks 7 to 12, holding 5 seconds at the end of the range.
Study: NCT06782542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Olutasidenib will be supplied as 150 mg capsules to be administered orally, twice per day (BID) on an empty stomach (fasting at least 1 hour before or 2 hours after a meal), starting on Cycle 1 Day 1, and will be given continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive Venetoclax as a 100mg tablet to be self-administered orally with a meal and water once daily, two hours after starting Olutasidenib administration, starting on Cycle 1 Day 1. The dosing regimen of Venetoclax is as follows:~* Cycle 1: Days 1 - 21 over a 28-day cycle~* Cycle 1 Week 1: Ramp-up dosing schedule up to 400mg (4 x 100mg/tablet)~* For participants with blast clearance: Cycle 2 and beyond: Days 1 - 14 over a 28-day cycle~* For participants with persistent clearance: Cycle 2 through 4: Days 1 - 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive Azacitidine 75 mg/m2 per day via subcutaneous (SC) injection or intravenous (IV) infusion on Days 1-7 of each cycle.
Study: NCT06791252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: genital hygiene education
Description: The pregnant women in the experimental group were given genital hygiene training individually and in their own homes by the researcher. During the training, the privacy of the client was observed and the researcher and the pregnant women were left alone in the room where the training would be given. Care was taken to ensure that the environment was quiet and calm while the training was given. It was preferred that the pregnant women be in the most comfortable position during the training.~The training was completed by explaining each topic in the training booklet in an average of 20-25 minutes.~Genital hygiene training content:~Session 1 (Day 1): After the introduction phase, information was given about the method to be followed in the study to the pregnant women who agreed to participate in the study. Then, the Minimum Informed Consent Form was given to these women, and the pregnant women who approved the form after reading it were included in the study. Pre-test data were collecte
Study: NCT06155292

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Communication Email
Description: This is a standard quarterly email communication without personalized performance metrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Report Card Email
Description: This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Report Card Email
Description: This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottom-Up Framing
Description: The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback.
Study: NCT04711902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab Placebo
Description: Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study: NCT06787183

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: CTV 25Gy/5Fx.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, d1-14，bid, q3w, 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5.0 mg/kg, q3w
Study: NCT06789653

Intervention type: DIAGNOSTIC_TEST
Intervention: p16INK4a mRNA level assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: p16INK4a mRNA level assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: organ-specific protein signatures assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.

Intervention type: DIAGNOSTIC_TEST
Intervention: organ-specific protein signatures assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.
Study: NCT06789679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, albumin-bound paclitaxel, S-1
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, albumin-bound paclitaxel
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
Study: NCT06788821

Intervention type: DIAGNOSTIC_TEST
Intervention: Description of the trend of major thyroid ultrasound biometric parameters
Description: Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Description of the trend of major thyroid ultrasound biometric parameters
Description: Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Description of the trend of major thyroid ultrasound biometric parameters
Description: Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.
Study: NCT06782490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05761899

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gene-Corrected Macrophages administered by bronchoscopic instillation
Description: This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
Study: NCT05374512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug. Provided in 100mg vials. IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Infusion. Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion. Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion. Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet. Oral route of administration. Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin mesylate
Description: IV infusion. Active comparator
Study: NCT04617314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
Study: NCT05281510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07523LS
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAP256V2LS
Description: Administered intravenously
Study: NCT05849168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
Study: NCT05268991

Intervention type: OTHER
Intervention: Geriatric Assessments and Frailty Indices
Description: Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
Study: NCT06128538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: we will implement 12 weeks of BFA. These sessions will be done every other week (total of 6 sessions over 12 weeks). During these sessions, Dr. Quinlan (Co-I) and another BFA-trained provider (Dr. Wilbur or Dr. Butler; also research team members) will perform the group BFA protocol with all 20 participants. During this 12-week acupuncture phase, participants will receive the same SMS messages twice a week to collect pain intensity scores. The group BFA protocol involves taking vitals for all patients (similar to a regular medical visit) and placing all 10 acupuncture needles (5 in each ear) while the patient remains seated in a chair. Once the acupuncture needles are placed, the patient will be asked to move around and remain in the room for 30 minutes (for any questions or medical concerns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale for Pain
Description: During the first 12 weeks of the trial, the research manager will collect weekly pain scores using the visual analog scale (pain scale 1-10). During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect pain scores using the visual analog scale at each acupuncture session immediately before and 30 minutes after the acupuncture protocol by the research team, and then twice a week thereafter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Roland-Morris Disability Questionnaire
Description: During the first 12 weeks of the trial, the research manager will collect weekly Roland -Morris Disability questionnaire data. During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect disability scores using the Roland-Morris Disability Questionnaire at each acupuncture session (6 sessions in total).
Study: NCT04026503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Long Walk Strong rehabilitation program
Description: Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Long Walk Strong rehabilitation program
Description: Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
Study: NCT05473910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC + TSC-100
Description: HA-1 positive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC + TSC-101
Description: HA-2 positive or HA-1 negative

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: SOC alone
Study: NCT05155345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
Study: NCT06029426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study: NCT05369832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study: NCT05421416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill
Study: NCT04887259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-051
Description: In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
Study: NCT04945460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 0.3 mg/kg
Description: Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Description: Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Study: NCT05323175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthesia injected under ultrasound guidance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medications
Description: Whatever the ED clinicians normally give for renal colic pain
Study: NCT06337188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental AAC
Description: Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic AAC
Description: Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
Study: NCT05432765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenotypic Personalized Medicine Dosing
Description: Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dosing
Description: Providers will decide on the combination of drug doses needed based on their overall assessment per standard of care.
Study: NCT05555706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B013+Nab-Paclitaxel
Description: B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.
Study: NCT05568069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)
Description: An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
Study: NCT04312126

Intervention type: DEVICE
Intervention: MRI system
Description: MRI system - GE Discovery MR750 3T

Intervention type: DEVICE
Intervention: MEG system
Description: MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
Study: NCT04948866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADRD-PC Program
Description: Included in arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADRD-PC Program
Description: Included in arm/group descriptions
Study: NCT05856526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spesolimab - solution for infusion
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab - solution for infusion
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to spesolimab - solution for infusion
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to spesolimab - solution for infusion
Description: Solution for infusion